NCT05373680

Efficacy and Safety of Metformin Versus Empagliflozin on Chronic Kidney Disease Progression

Clinical Study Evaluating the Efficacy and Safety of Metformin Versus Empagliflozin for Halting Chronic Kidney Disease Progression

• Status: Completed
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 118 (actual)
• Sponsor: Tanta University · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This randomized controlled trial aims at evaluating the efficacy and safety of the antidiabetics metformin versus empagliflozin on chronic kidney disease (CKD) progression in patients with CKD stages 2 or/and 3.

Conditions

• Renal Insufficiency, Chronic

Interventions

Type	Name	Description
DRUG	Metformin	Patients will receive metformin 1000 mg PO daily added to their usual therapy for the management of CKD (including the management of predisposing causes with other supportive care).
DRUG	Empagliflozin	Patients will receive empagliflozin 10 mg daily PO added to their usual therapy for the management of CKD (including the management of predisposing causes with other supportive care).
OTHER	Control	Patients will receive their usual therapy for the management of CKD (including the management of predisposing causes with other supportive care).

Timeline

• Start date: 2022-01-01
• Primary completion: 2024-04-01
• Completion: 2024-04-01
• First posted: 2022-05-13
• Last updated: 2025-08-14

Locations

2 sites across 1 country: Egypt

Regulatory

• FDA-regulated drug study